Möchten Sie immer auf dem neuesten Stand bleiben?

-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10,...

The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of...

BELLEVUE, Wash., March 05, 2026 (GLOBE NEWSWIRE) -- Truveta today announced its participation as a contributing author to a new peer-reviewed Policy Forum article in Science titled “Governing...

-- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:...

-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading...

BELLEVUE, Wash., Feb. 10, 2026 (GLOBE NEWSWIRE) -- A new peer-reviewed study led by Truveta Research and collaborators finds that the US Food and Drug Administration’s (FDA) March 2024 expansion of...

ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a leading biomedical innovator making fertility and non-surgical permanent birth control more...

New Green Hemp, Inc. Appoints Attorney Michael Minardi to Board of Directors to Strengthen Governance and Regulatory Strategy

-- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE...

Millions living with chronic pain now have a new, FDA-cleared, non-invasive, and drug-free treatment option with Magstim Magnetic Stimulation.